Genome-wide DNA hypomethylation plays has an important role in genomic instability and colorectal carcinogenesis. However, the relationship between cellular DNA methylation level and patient outcome remains uncertain. Using 643 colon cancers in two independent prospective cohorts, we quantified DNA methylation in repetitive long interspersed nucleotide element-1 (LINE-1) elements using pyrosequencing, which is a good indicator of global DNA methylation level. We used Cox proportional hazard models to calculate hazard ratios (HRs) of colon cancer -specific and overall mortality, adjusting for patient and tumoral features, including CpG island methylator phenotype (CIMP). Statistical tests were two-sided. LINE-1 hypomethylation was linearly associated with a statistically significant increase in colon cancer -specific mortality (for a 30% decrease in LINE-1 methylation: multivariable HR = 2.37, 95% confidence interval [CI] = 1.42 to 3.94; P trend < .001) and overall mortality (multivariable HR = 1.85, 95% CI = 1.25 to 2.75; P trend = .002). The association was consistent across the two independent cohorts and strata of clinical and molecular characteristics, including sex, age, tumor location, stage, and CIMP, microsatellite instability, KRAS , BRAF , p53, and chromosomal instability status. In conclusion, tumoral LINE-1 hypomethylation is independently associated with shorter survival among colon cancer patients. LINE-1 methylation level and survival time ( P = .31 for colon cancer -specifi c mortality and P = .73 for overall mortality). The primary statistical analysis was the linear test for trend with LINE-1 methylation as a continuous variable, to avoid the possibility of selecting cut points with maximal P values. We also performed analyses using categories ( Supplementary  Table 1 , available online) that were based on the overall distribution of LINE-1 methylation levels. We used SAS version 9.1 (SAS Institute, Cary, NC) for statistical analyses. All statistical tests were two-sided, and P values less than .05 were considered statistically signifi cant.
BRIEF COMMUNICATION
performed using a mouse monoclonal antibody (clone DO-1, dilution 1:50; Calbiochem, San Diego, CA) as previously described ( 23 ) . Bisulfi te DNA treatment and real-time polymerase chain reaction [MethyLight ( 24 ) ] were validated and performed ( 25 ) . We quantifi ed promoter methylation in eight CpG island methylator phenotype (CIMP) -specifi c promoters ( CACNA1G , CDKN2A , CRABP1 , IGF2 , MLH1 , NEUROG1 , RUNX3 , and SOCS1 ) ( 26 -28 ) . CIMP-high was defi ned as methylation in at least six of the eight promoters ( 26 ) .
To accurately quantify relatively high LINE-1 methylation levels, we used pyrosequencing ( 29 ) . LINE-1 methylation as measured by pyrosequencing has been reported to be a good indicator of cellular 5-methylcytosine level (ie, global DNA methylation level) ( 3 , 5 , 30 ) . LINE-1 methylation levels in the 643 tumors were approximately normally distributed (mean = 61.2%; standard deviation = 9.4%) ( Supplementary Figure 1 , available online).
Cox proportional hazard models were used to calculate hazard ratios (HRs) of death according to LINE-1 methylation level, adjusted for age, sex, year of diagnosis, tumor location, stage, grade, and CIMP, MSI, CIN, KRAS , BRAF , and p53 status. The proportionality of hazards assumption was satisfi ed by evaluating time-dependent variables, which were the cross product of DNA methylation is a major epigenetic mechanism in X-chromosome inactivation, imprinting, and repression of endogenous retroviruses ( 1 , 2 ) . Repetitive nucleotide elements (eg, long interspersed nucleotide element-1 [LINE-1]) contain numerous CpG dinucleotides, and previous studies ( 3 -5 ) have shown that LINE-1 methylation level has been reported to be a good indicator of cellular 5-methylcytosine level (ie, global DNA methylation level). Genomewide DNA hypomethylation has an im portant role in genomic instability by reactivating transposable DNA sequences during colorectal carcinogenesis ( 1 , 6 -15 ) . However, the infl uence of global DNA hypomethylation on the prognosis of colon cancer patients remains uncertain.
We used two independent prospective cohort studies: the Nurses ' Health Study (121 700 women followed since 1976) ( 16 , 17 ) and the Health Professionals Follow-up Study (51 500 men followed since 1986) ( 17 , 18 ). Every 2 years, participants were sent follow-up questionnaires to update information on potential risk factors and to identify newly diagnosed cancer, including colon cancer ( 16 -18 ( 19 ) .
KRAS and BRAF sequencing and analyses for microsatellite instability (MSI) and loss of heterozygosity (chromosomal instability, CIN) were performed on DNA from paraffi n-embedded tissue ( 20 -22 ) . Immunohistochemistry for p53 was
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Shuji Ogino , Katsuhiko Nosho , Gregory J. Kirkner , Takako Kawasaki , Andrew T. Chan , Eva S. Schernhammer , Edward L. Giovannucci , Charles S. Fuchs LINE-1 methylation level and survival time ( P = .31 for colon cancer -specifi c mortality and P = .73 for overall mortality). The primary statistical analysis was the linear test for trend with LINE-1 methylation as a continuous variable, to avoid the possibility of selecting cut points with maximal P values. We also performed analyses using categories ( Supplementary Table 1 , available online) that were based on the overall distribution of LINE-1 methylation levels. We used SAS version 9.1 (SAS Institute, Cary, NC) for statistical analyses. All statistical tests were two-sided, and P values less than .05 were considered statistically signifi cant.
LINE-1 hypomethylation was associated with a statistically signifi cant increase in colon cancer -specifi c mortality (univariate analysis P trend < .001 and multivariable analysis P trend < .001) ( Table 1 ) . For a 30% decrease in LINE-1 methylation, the multivariable HR for colon cancer -specifi c mortality was 2.37 (95% confi dence interval [CI] = 1.42 to 3.94). LINE-1 hypomethylation was also associated with a statistically signifi cant increase in overall mortality (univariate analysis P trend = .008 and multivariable analysis P trend = .002).
To facilitate display of the results, we also grouped patients according to four categories of LINE-1 methylation ( ≥ 75%, 60% -75%, 45% -60%, and <45%). Compared with patients who had 75% or greater LINE-1 methylated tumors, those with less than 45% LINE-1 methylation had higher colon cancer -specifi c mortality (mul tivariable HR = 5.00; 95% CI = 1.92 to 13.1) and a similar increase in overall mortality (multivariable HR = 4.73; 95% CI = 2.20 to 10.2) ( Table 1 ).
The colon cancer -specifi c survival probability at 5 years was progressively lower as LINE-1 methylation level declined ( ≥ 75% LINE-1 methylation: survival probability = 0.85, 95% CI = 0.69 to 0.93; 60% -75% methylation: survival probability = 0.83, 95% CI = 0.79 to 0.87; 45% -60% methylation: survival probability = 0.74, 95% CI = 0.68 to 0.80; and <45% methylation: survival probability = 0.54, 95% CI = 0.35 to 0.70; P < .001) ( Figure 1, A ) . Similarly, overall survival at 5 years was statistically signifi cantly lower for patients with relatively hypomethylated LINE-1 ( ≥ 75% LINE-1 methylation: survival probability = 0.80, 95% CI = 0.64 to 0.89; 60% -75% methylation: survival probability = 0.77, 95% CI = 0.72 to 0.81; 45% -60% methylation: survival probability = 0.71, 95% CI = 0.64 to 0.76; and <45% methylation: survival probability = 0.48, 95% CI = 0.30 to 0.64; P = .02) ( Figure 1, B ) .
We examined the possibility of a nonlinear relationship between LINE-1 hypomethylation and mortality by using a nonparametric method with restricted cubic splines ( 31 ), which was independent of predetermined LINE-1 categorizations. The HRs for colon cancer -specifi c and overall mortality increased continuously with decreasing LINE-1 methylation ( Figure 1, C and D ) . Notably, the lower limits of the 95% confi dence intervals remained above 1.0 for all values of LINE-1 methylation, suggesting a robust association between LINE-1 hypomethylation and mortality.
We also generated a receiver operator characteristics curve for the prediction of 5-year colon cancer -specifi c survival using all possible cutoffs (positive vs negative) for LINE-1 hypomethylation (area under the curve = 0.56) ( Supplementary Figure  2 , available online). This result implies that there were limitations to using LINE-1 methylation as a binary diagnostic test to predict patient outcome at a fi xed time point.
CONTEXT AND CAVEATS
Prior knowledge DNA hypomethylation is involved in genomic instability and colorectal carcinogenesis, but whether it is associated with the survival of colon cancer patients is unknown.
Study design
Prospective study of two colon cancer patient populations to evaluate the association between DNA methylation, which was assayed in long interspersed nucleotide element-1 (LINE-1), and survival. Clinical and molecular characteristics of the tumors were included in the analyses. Contribution LINE-1 hypomethylation was associated with higher colon cancer -specific and overall mortality, independent of other tumor characteristics.
Implications LINE-1 hypomethylation may be a prognostic indicator of patient survival in colon cancer.
Limitations
Treatment data were limited for the patients studied. The patients were all health care professionals, and it is unknown whether the findings are applicable to the general population. The mechanism involved is unknown. survival probability at 5 years = 0.80, 95% CI = 0.64 to 0.89; 60% -75% methylation: survival probability at 5 years = 0.77, 95% CI = 0.72 to 0.81; 45% -60% methylation: survival probability at 5 years = 0.71, 95% CI = 0.64 to 0.76; and <45% methylation: survival probability at 5 years = 0.48, 95% CI = 0.30 to 0.64). Vertical bars , 95% confi dence intervals at 2-year intervals. P values (two-sided) were calculated using the logrank test. C ) Smoothing spline plot of unadjusted hazard ratios (HRs) for colon cancer -specifi c mortality according to LINE-1 methylation level (%). D ) Smoothing spline plot of unadjusted HRs for overall mortality according to LINE-1 methylation level (%). Hatched lines , 95% confi dence intervals.
From the Editors
Finally, we examined the infl uence of LINE-1 hypomethylation on colon cancer -specifi c mortality across strata of other clinical and molecular characteristics ( Supplementary Figure 3 , available online) . The association between LINE-1 hypomethylation and colon cancer -specifi c mortality was not modifi ed by any of the clinical or molecular variables nor was it different between the two cohorts (the Health Professionals Follow-up Study and the Nurses ' Health Study; P interaction = .74).
Although prognostic factors in colon cancer have been extensively studied ( 32 -38 ) , little is known regarding the prognostic value of global DNA hypomethylation. The relationship between genome-wide DNA hypomethylation and clinical outcome has been examined in prostate, liver, and ovarian cancers and leukemia ( 39 -42 ) . Among those studies, only the study of chronic myeloid leukemia ( 42 ) showed a statistically signifi cant association between global DNA hypomethylation and poor survival. In colon cancer, Frigola et al. ( 43 ) analyzed 93 tumors using the amplifi cation of intermethylated sites (AIMS) method and observed a trend toward poor survival in DNA hypomethylated tumors; however, the results did not reach statistical signifi cance.
The mechanism by which global DNA hypomethylation may confer a poor prognosis remains speculative. Genome-wide DNA hypomethylation has been associated with genomic instability ( 7 -15 ) , which may confer poor prognosis. Transcriptional dysregulation might be another possible mechanism, and activation of proto-oncogenes, endogenous retroviruses, or transposable elements might affect tumor aggressiveness. A third possible mechanism involves infl ammatory mediators and oxidative stress; the latter has been associated with genomic DNA hypomethylation ( 44 , 45 ) . Activation of the infl ammatory pathway has been associated with poor prognosis in colon cancer ( 46 ) .
The study has potential limitations. In the two cohorts, data on cancer treatment were limited. It is unlikely that chemotherapy use differed according to tumoral LINE-1 methylation level, since such data were not available to patients or treating physicians. Other potential study limitations include a nonperfect correlation (correlation coeffi cient < 1) between LINE-1 methylation and global DNA methylation level and that these health professionalsbased cohort studies may not be completely representative of the general population.
In summary, the results from this large prospective cohort study suggest that genome-wide DNA hypomethylation as measured in LINE-1 is independently associated with poor survival among patients with colon cancer. The adverse effect of LINE-1 hypomethylation on prognosis persisted across the two independent prospective cohort studies as well as strata of other clinical or tumoral characteristics. These fi ndings may have considerable clinical implications. Future studies are needed to confi rm this association as well as examine potential mechanisms by which genome-wide DNA hypomethylation affects tumor behavior.
